Orchestra BioMed Holdings, Inc. (OBIO)

NASDAQ: OBIO · Real-Time Price · USD

2.890

+0.010 (0.35%)

Jul 3, 2025, 1:00 PM - Market closed

Orchestra BioMed Holdings Employees

Orchestra BioMed Holdings had 70 employees as of December 31, 2024. The number of employees increased by 14 or 25.00% compared to the previous year.

Employees

70

Change (1Y)

14

Growth (1Y)

25.00%

Revenue / Employee

$41,229

Profits / Employee

-$947,371

Market Cap

110.72M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	70	14	25.00%
Dec 31, 2023	56	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	94,300
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

OBIO News

18 days ago - Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025 - GlobeNewsWire
5 weeks ago - Orchestra BioMed: Two Best-In-Class Devices And Promising Partnerships - Seeking Alpha
7 weeks ago - Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones - GlobeNewsWire
2 months ago - Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure - GlobeNewsWire
2 months ago - Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon - GlobeNewsWire
2 months ago - Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences - GlobeNewsWire
2 months ago - Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting - GlobeNewsWire
2 months ago - Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy - GlobeNewsWire